News >

Nivolumab, Elotuzumab Receive Breakthrough Therapy Designations for Types of Blood Cancer

Silas Inman @silasinman
Published: Monday, May 19, 2014

Bristol-Myers SquibbOver the course of only a few days, two drugs that will be commercialized by Bristol-Myers Squibb (BMS), nivolumab and elotuzumab, have each been granted breakthrough therapy designations by the FDA for the treatment of two different types of blood cancers.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication